Biotech | December 24, 2025
Enveda launches Phase 1 trial for first-in-class Oral IBD therapy
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The initiative is focused on a problem that continues to plague cancer outcomes in India
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Subscribe To Our Newsletter & Stay Updated
